{"id":"NCT05096208","sponsor":"Pfizer","briefTitle":"Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to â‰¤49 Years of Age","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-21","primaryCompletion":"2022-04-04","completion":"2022-04-04","firstPosted":"2021-10-27","resultsPosted":"2023-04-12","lastUpdate":"2023-04-12"},"enrollment":1028,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["RSV"],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF (Group 1)","otherNames":[]},{"type":"BIOLOGICAL","name":"RSVpreF (Group 2)","otherNames":[]},{"type":"BIOLOGICAL","name":"RSVpreF (Group 3)","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"RSVpreF vaccine Group 1","type":"EXPERIMENTAL"},{"label":"RSVpreF vaccine Group 2","type":"EXPERIMENTAL"},{"label":"RSVpreF vaccine Group 3","type":"EXPERIMENTAL"},{"label":"Placebo dose","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.","primaryOutcome":{"measure":"Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots","timeFrame":"1 month (27 to 42 days window) after vaccination on Day 1","effectByArm":[{"arm":"Group 1: RSVpreF Lot 1","deltaMin":25238.1,"sd":null},{"arm":"Group 2: RSVpreF Lot 2","deltaMin":25207.5,"sd":null},{"arm":"Group 3: RSVpreF Lot 3","deltaMin":24130.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["38616438"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3671014"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":247},"commonTop":["Fatigue (FATIGUE)","Headache (HEADACHE)","Injection site pain (PAIN AT INJECTION SITE)","Myalgia (MUSCLE PAIN)","Arthralgia (JOINT PAIN)"]}}